Second Cellectis CAR-T Therapy On Clinical Hold, Dosing Could Be Issue
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
You may also be interested in...
Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.
Poseida’s technologies are designed to deliver safer, more effective cell and gene therapies, but the first trial for its autologous PSMA-targeting CAR-T therapy was put on a clinical hold after a patient died.
The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.